Two new oral disease modifying therapies in relapsing remitting multiple sclerosis

被引：0
|
作者：
Lebrun, C. [1 ]
de Seze, J. [2 ]
机构：
[1] Hop Louis Pasteur, Serv Neurol, F-06002 Nice 1, France
[2] Hop Hautepierre, Serv Neurol, F-67000 Strasbourg, France
来源：
REVUE NEUROLOGIQUE | 2014年 / 170卷 / 12期
关键词：
PLACEBO-CONTROLLED PHASE-3; DOUBLE-BLIND; TERIFLUNOMIDE; TRIAL; BG-12;
D O I：
10.1016/j.neurol.2014.11.002
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：721 / 722
页数：2
相关论文
共 50 条
  • [21] Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Abdel-mannan, Omar A.
    Manchoon, Celeste
    Rossor, Thomas
    Southin, Justine-Clair
    Tur, Carmen
    Brownlee, Wallace
    Byrne, Susan
    Chitre, Manali
    Coles, Alasdair
    Forsyth, Rob
    Kneen, Rachel
    Mankad, Kshitij
    Ram, Dipak
    West, Siobhan
    Wright, Sukhvir
    Wassmer, Evangeline
    Lim, Ming
    Ciccarelli, Olga
    Hemingway, Cheryl
    Hacohen, Yael
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (04):
  • [22] Which drugs are most effective for relapsing remitting multiple sclerosis? A network metaanalysis of disease modifying therapies
    Fogarty, E.
    Schmitz, S.
    Walsh, C.
    Tubridy, N.
    Barry, M.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 272 - 272
  • [23] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
  • [24] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [25] The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Marco Biolato
    Assunta Bianco
    Matteo Lucchini
    Antonio Gasbarrini
    Massimiliano Mirabella
    Antonio Grieco
    CNS Drugs, 2021, 35 : 861 - 880
  • [26] COST OFFSET ANALYSIS OF INTERFERON BETA DISEASE MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Beckerman, R.
    Locklear, J. C.
    Smith, N. J.
    Phillips, A. L.
    VALUE IN HEALTH, 2015, 18 (07) : A752 - A752
  • [27] Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
    Lucchetta, Rosa C.
    Tonin, Fernanda S.
    Borba, Helena H. L.
    Leonart, Leticia P.
    Ferreira, Vinicius L.
    Bonetti, Aline F.
    Riveros, Bruno S.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    CNS DRUGS, 2018, 32 (09) : 813 - 826
  • [28] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [29] The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Biolato, Marco
    Bianco, Assunta
    Lucchini, Matteo
    Gasbarrini, Antonio
    Mirabella, Massimiliano
    Grieco, Antonio
    CNS DRUGS, 2021, 35 (08) : 861 - 880
  • [30] No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
    Richard Nixon
    Niklas Bergvall
    Davorka Tomic
    Nikolaos Sfikas
    Gary Cutter
    Gavin Giovannoni
    Advances in Therapy, 2014, 31 : 1134 - 1154
12345